Cyclobutanecarbonyl chloride → N-[1-(5-Cyclobutyl-[1,2,4]oxadiazol-3-yl)-piperidin-4-yl]-N-cyclopropyl-4-oxazol-5-yl-benzamide
반응식
[CH:1]1([N:4]([CH:18]2[CH2:23][CH2:22][N:21]([C:24](=[NH:27])[NH:25][OH:26])[CH2:20][CH2:19]2)[C:5](=[O:17])[C:6]2[CH:11]=[CH:10][C:9]([C:12]3[O:16][CH:15]=[N:14][CH:13]=3)=[CH:8][CH:7]=2)[CH2:3][CH2:2]1.[CH:28]1([C:32](Cl)=O)[CH2:31][CH2:30][CH2:29]1>>[CH:28]1([C:32]2[O:26][N:25]=[C:24]([N:21]3[CH2:22][CH2:23][CH:18]([N:4]([CH:1]4[CH2:3][CH2:2]4)[C:5](=[O:17])[C:6]4[CH:11]=[CH:10][C:9]([C:12]5[O:16][CH:15]=[N:14][CH:13]=5)=[CH:8][CH:7]=4)[CH2:19][CH2:20]3)[N:27]=2)[CH2:31][CH2:30][CH2:29]1참가 물질
3
실험 절차
The title compound is prepared from N-cyclopropyl-N-[1-(N-hydroxycarbamimidoyl)-piperidin-4-yl]-4-oxazol-5-yl-benzamide and cyclobutanecarbonyl chloride following a procedure analogous to that described in Example 47. LC (method 2): tR=1.27 min; Mass spectrum (ESI+): m/z=434 [M+H]+.
출처 및 근거
- ORD 기록
- ord-d940fddcb6a94b3e9d31c9ecd2691295
- 출처 데이터셋
- uspto-grants-2014_09